Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
2Inject once weekly with the Zepbound pen, on the same day each week
Safety in patients with existing mild-moderate liver disease Correlation between weight loss and estimated liver fat reduction TRIUMPH-2 (Ongoing, Expected 2026) Primary Endpoints: Weight loss in diabetic patients HbA1c reduction Secondary Endpoints (Liver): Liver enzymes Metabolic markers Diabetic Population Note: Higher prevalence of MASLD/NASH (~40-50%), so liver benefits particularly important in this group
Special considerations
Consistency is Key Antioxidant levels do not stay elevated forever
Losing weight too fast and being underweight can lower your oestrogen levels
.webp)
US$ 20.86
US$ 29.55
:max_bytes(150000):strip_icc()/GettyImages-1226643512-81f272defa784232ad08fa77f1ac7452.jpg)
US$ 22.26
US$ 22.40
US$ 27.97
